MiR-34b/c rs4938723 Polymorphism Significantly Decreases the Risk of Digestive Tract Cancer: Meta-analysis

  • Ji, Tian-Xing (Department of Clinical Laboratory, the Second Affiliated Hospital of Guangzhou Medical University) ;
  • Zhi, Cheng (Department of Clinical Pathology, the Second Affiliated Hospital of Guangzhou Medical University) ;
  • Guo, Xue-Guang (Department of Clinical Laboratory, the Third Affiliated Hospital of Guangzhou Medical University) ;
  • Zhou, Qiang (Department of Clinical Laboratory, the Second Affiliated Hospital of Guangzhou Medical University) ;
  • Wang, Guo-Qiang (Department of Gastrointestinal Surgery, Lab of Surgery, the Second Affiliated Hospital of Guangzhou Medical University) ;
  • Chen, Bo (Department of Clinical Laboratory, the Second Affiliated Hospital of Guangzhou Medical University) ;
  • Ma, Fei-Fei (Department of VIP Obstetrics, the Second Affiliated Hospital of Guangzhou Medical University)
  • Published : 2015.09.02


Background: Previous studies investigating the association between miR-34b/c rs4938723 polymorphism and cancer risk showed inconclusive. Here, we performed meta-analysis to investigate the association between miR- 34b/c rs4938723 polymorphism and digestive cancer risk. Materials and Methods: Literature database including PubMed, OVID, Chinese National Knowledge Infrastructure (CNKI) were searched for publications concerning the association between the miR-34b/c rs4938723 polymorphism and digestive cancer risk. Results: A total of 6 studies consisting of 3246 cases and 3568 controls were included in this meta-analysis. The combined analysis suggested the miR-34b/c rs4938723 polymorphism significantly reduced digestive cancer risk under allelic model, homogeneous co-dominant model and recessive model (C vs T: OR=0.88, 95%CI=0.82-0.95, p-value=0.001; CC vs TT: OR =0.67, 95%CI=0.57-0.80, p-value=0.000; CC vs TT/TC: OR=0.68, 95%CI=0.58-0.80, p-value=0.000). Q-test and I2 test revealed no significant heterogeneity in all genotype comparisons. The Begger's funnel plot and Egger's test did not show significant publication bias. Conclusions: The current evidence supports the conclusion that the miR-34b/c rs4938723 polymorphism decreases an individual's susceptibility to digestive cancers.


  1. Bensen JT, Tse CK, Nyante SJ, et al (2013). Association of germline microRNA SNPs in pre-miRNA flanking region and breast cancer risk and survival: the carolina breast cancer study. Cancer Causes Control, 24, 1099-109.
  2. Chen X, Hu H, Guan X, et al (2012). CpG island methylation status of miRNAs in esophageal squamous cell carcinoma. Int J Cancer, 130, 1607-13.
  3. Corney DC, Flesken-Nikitin A, Godwin AK, et al (2007). MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesionindependent growth. Cancer Res, 67, 8433-8.
  4. Corney DC, Hwang CI, Matoso A, et al (2010). Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res, 16, 1119-28.
  5. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  6. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
  7. Gao LB, Li LJ, Pan XM, et al (2013). A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem, 394, 415-20.
  8. Han Y, Pu R, Han X, et al (2013). Associations of pri-miR- 34b/c and pre-miR-196a2 polymorphisms and their multiplicative interactions with hepatitis B virus mutations with hepatocellular carcinoma risk. PLoS One, 8, 58564.
  9. He L, He X, Lim LP, et al (2007). A microRNA component of the p53 tumour suppressor network. Nature, 447, 1130-4.
  10. Kalimutho M, Di Cecilia S, Del Vecchio Blanco G, et al (2011). Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer, 104, 1770-8.
  11. Li L, Wu J, Sima X, et al (2013). Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma. Tumour Biol, 34, 1919-23.
  12. Lujambio A, Calin GA, Villanueva A, et al (2008). A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A, 105, 13556-61.
  13. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
  14. Normand SL (1999). Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med, 18, 321-59.<321::AID-SIM28>3.0.CO;2-P
  15. Oh J, Kim JW, Lee BE, et al (2014). Polymorphisms of the primiR- 34b/c promoter and TP53 codon 72 are associated with risk of colorectal cancer. Oncol Rep, 31, 995-1002.
  16. Pan XM, Sun RF, Li ZH, et al (2015). Pri-miR-34b/c rs4938723 polymorphism is associated with a decreased risk of gastric cancer. Genet Test Mol Biomarkers.
  17. Son MS, Jang MJ, Jeon YJ, et al (2013). Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene, 524, 156-60.
  18. Suzuki H, Yamamoto E, Nojima M, et al (2010). Methylationassociated silencing of microRNA-34b/c in gastric cancer and its involvement in an epigenetic field defect. Carcinogenesis, 31, 2066-73.
  19. Suzuki R, Yamamoto E, Nojima M, et al (2014). Aberrant methylation of microRNA-34b/c is a predictive marker of metachronous gastric cancer risk. J Gastroenterol, 49, 1135-44.
  20. Tao T, Chen S, Xu B, et al (2014). Association between hsamiR- 34b/c rs4938723 T > C promoter polymorphism and cancer risk: a meta-analysis based on 6,036 cases and 6,204 controls. Chin J Cancer Res, 26, 315-22.
  21. Tian Q, Jia J, Ling S, et al (2014). A causal role for circulating miR-34b in osteosarcoma. Eur J Surg Oncol, 40, 67-72.
  22. Toyota M, Suzuki H, Sasaki Y, et al (2008). Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res, 68, 4123-32.
  23. Vogt M, Munding J, Gruner M, et al (2011). Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch, 458, 313-22.
  24. Wang LQ, Kwong YL, Wong KF, et al (2014). Epigenetic inactivation of mir-34b/c in addition to mir-34a and DAPK1 in chronic lymphocytic leukemia. J Transl Med, 12, 52.
  25. Wang Z, Wu J, Zhang G, et al (2013). Associations of miR- 499 and miR-34b/c polymorphisms with susceptibility to hepatocellular carcinoma: an evidence-based evaluation. Gastroenterol Res Pract, 2013, 719202.
  26. Xu Y, Liu L, Liu J, et al (2011). A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer, 128, 412-7.
  27. Xue W, Zhu M, Wang Y, et al (2015). Association between PLCE1 rs2274223 A > G polymorphism and cancer risk: proof from a meta-analysis. Sci Rep, 5, 7986.
  28. Yang C, Ma X, Liu D, et al (2014). Promoter polymorphisms of miR-34b/c are associated with risk of gastric cancer in a Chinese population. Tumour Biol, 35, 12545-54.
  29. Yi DH, Wang BG, Zhong XP, et al (2014). Pri-miR-34b/c rs4938723 TC heterozygote is associated with increased cancer risks: evidence from published data. Tumour Biol, 35, 11967-75.
  30. Yin J, Wang X, Zheng L, et al (2013). Hsa-miR-34b/c rs4938723 T>C and hsa-miR-423 rs6505162 C>A polymorphisms are associated with the risk of esophageal cancer in a Chinese population. PLoS One, 8, 80570.
  31. Zhang J, Huang X, Xiao J, et al (2014a). Pri-miR-124 rs531564 and pri-miR-34b/c rs4938723 polymorphisms are associated with decreased risk of esophageal squamous cell carcinoma in Chinese populations. PLoS One, 9, 100055.
  32. Zhang S, Qian J, Cao Q, et al (2014b). A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population. Mutagenesis, 29, 149-54.

Cited by

  1. Evaluation of the pri-miR-34b/c rs4938723 polymorphism and its association with breast cancer risk vol.5, pp.1, 2016,
  2. Association Between Polymorphisms in the Promoter Region of microRNA-34b/c and the Chemoradiotherapy Efficacy for Locally Advanced Esophageal Squamous Cell Carcinoma in Chinese Han Population pp.1532-2807, 2017,
  3. Association between miR-34b/c rs4938723 polymorphism and risk of cancer: An updated meta-analysis of 27 case-control studies vol.120, pp.3, 2018,